Evidence map›Paper›PMID 41438040›Full record

ArticleiScience2025

Lithium attenuates HIV-1 latency reversal in an autophagy-independent way.

Ana-Luiza Abdalla, Gabriel Guajardo-Contreras, Bao-An Chau, Meijuan Niu, Thomas Murooka, Andrew J Mouland

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ana-Luiza AbdallaLady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Gabriel Guajardo-ContrerasLady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Bao-An ChauLady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Meijuan NiuLady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Thomas MurookaRady Faculty of Health Science, Department of Immunology, University of Manitoba, Winnipeg, MB R3E 3P5 Canada.
Andrew J MoulandLady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The major barrier to eradicate HIV-1 is its persistence in latently infected cells. Inducing deep latency to prevent HIV-1 reactivation in the absence of combined antiretroviral therapy (cART) remains a primary goal. Here, we evaluated the repurposing of lithium as an HIV-1 latency-promoting drug (LPA). We demonstrated that lithium attenuates virus reactivation in three cell models for HIV-1 latency. Lithium induced autophagy in CD4

Indexed as

Cell biologyPharmacologyVirology

Identifiers

PMID41438040
PMCPMC12719738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.